Fundraising Fox

Bellerophon Therapeutics

Warren, US · Founded 2015 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

PS
Parag ShahVice President of Business Operations
MD
Martin DekkerVice President of Engineering and Manufacturing
PF
Peter FernandesChief Regulatory and Safety Officer
FT
Fabian TenenbaumChief Executive Officer and Director
DQ
Deborah QuinnChief Medical Officer
RN
Robert NelsenNamed on SEC filing
AW
Adam WeinsteinNamed on SEC filing
AB
Aldo BelloniNamed on SEC filing
MM
Martin MeglassonNamed on SEC filing
HP
Howard PienNamed on SEC filing
RH
Reinilde HeyrmanNamed on SEC filing
BR
Bryan RobertsNamed on SEC filing

Investors · 1

New Mountain CapitalNew York

Reported raises · per SEC filings

Form D private placements

$25M disclosed across 4 rounds · 2014–2017

▶$23.4MraisedOct 2017 · 11 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jens LuehringDirector
  • Mary Ann CloydDirector
  • Adam B. WeinsteinDirector
  • Martin DekkerExecutive Officer
  • Deborah A. QuinnExecutive Officer
  • Amy EdmondsExecutive Officer
  • Scott BruderDirector
  • Jonathan M. PeacockDirector
  • Peter FernandesExecutive Officer
  • Parag ShahExecutive Officer
  • Andre V. MouraDirector
  • Daniel TasseDirector
  • Naseem P. AminDirector
  • Megan SchoepsExecutive Officer
  • Fabian TenenbaumExecutive Officer, Director
Offering amount
$23.4M
Amount sold
$23.4M
Sales commissions
$650K
Placement agents
Angel Pond Capital LLC
First sale
Sep 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedMay 2017 · 7 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Naseem AminDirector
  • Jens LuehringDirector
  • Mary Ann CloydDirector
  • Parag ShahExecutive Officer
  • Martin DekkerExecutive Officer
  • Andre MouraDirector
  • Peter FernandesExecutive Officer
  • Jonathan PeacockDirector
  • Scott BruderDirector
  • Daniel TasseDirector
  • Fabian TenenbaumExecutive Officer, Director
  • Deborah QuinnExecutive Officer
  • Adam WeinsteinDirector
  • Megan SchoepsExecutive Officer
  • Amy EdmondsExecutive Officer
Offering amount
$1.6M
Amount sold
$1.6M
Sales commissions
$210K
Placement agents
H.C. Wainwright & Co., LLC
First sale
May 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1raisedJul 2014 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David AbramsExecutive Officer
  • Aldo BelloniDirector
  • Martin MeglassonExecutive Officer
  • Manesh NaiduExecutive Officer
  • Jonathan PeacockExecutive Officer, Director
  • Howard PienDirector
  • Daniel TasseDirector
  • Adam WeinsteinDirector
  • Matthew HoltDirector
  • Robert NelsenDirector
  • Andre MouraDirector
  • Reinilde HeyrmanExecutive Officer
Offering amount
$1
Amount sold
$1
First sale
Jun 2014
Incorporated
Limited Liability Company, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1raisedFeb 2014 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Andre MouraDirector
  • Robert NelsenDirector
  • Adam WeinsteinDirector
  • Aldo BelloniDirector
  • Daniel TasseExecutive Officer, Director
  • Martin MeglassonExecutive Officer
  • Howard PienDirector
  • Reinilde HeyrmanExecutive Officer
  • Bryan RobertsDirector
  • David AbramsExecutive Officer
  • Manesh NaiduExecutive Officer
  • Matthew HoltDirector
Offering amount
$1
Amount sold
$1
First sale
Feb 2014
Incorporated
Limited Liability Company, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who are Bellerophon Therapeutics's investors?
Bellerophon Therapeutics's investors include New Mountain Capital.
How much funding has Bellerophon Therapeutics raised?
Bellerophon Therapeutics has disclosed $25M raised across 4 rounds.
Where is Bellerophon Therapeutics headquartered?
Bellerophon Therapeutics is headquartered in Warren, US.